Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Rhythm Pharmaceuticals (RYTM) vs. Competitors

1 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
MX:RYTMRhythm PharmaceuticalsMXN 1,860.00MXN 146.97B-38.67-8.15%Strong BuyUnlock the MX:RYTM analyst price target with TipRanks PremiumMX:RYTMUnlock the MX:RYTM top-analyst price target with TipRanks Premium
QUREuniQure$24.59$1.59B-6.94-20.28%Strong BuyUnlock the QURE analyst price target with TipRanks PremiumMX:RYTM vs QUREUnlock the QURE top-analyst price target with TipRanks Premium
VKTXViking Therapeutics$28.44$3.65B-5.27-29.95%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumMX:RYTM vs VKTXUnlock the VKTX top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$20.95$1.55B-5.37-39.91%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumMX:RYTM vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
MBXMBX Biosciences, Inc.$57.72$2.80B-18.86131.71%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumMX:RYTM vs MBXUnlock the MBX top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$14.38$1.85B-5.75-44.69%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumMX:RYTM vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
MX:RYTMRhythm Pharmaceuticals1860.00-165.00-8.15%
QUREuniQure24.59-5.54-18.38%
VKTXViking Therapeutics28.44-12.34-30.26%
GPCRStructure Therapeutics, Inc. Sponsored ADR20.95-14.97-41.68%
MBXMBX Biosciences, Inc.57.7233.12134.63%
KLRAKailera Therapeutics, Inc.14.38-11.62-44.69%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts